JP5745419B2 - 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法 - Google Patents

細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法 Download PDF

Info

Publication number
JP5745419B2
JP5745419B2 JP2011535119A JP2011535119A JP5745419B2 JP 5745419 B2 JP5745419 B2 JP 5745419B2 JP 2011535119 A JP2011535119 A JP 2011535119A JP 2011535119 A JP2011535119 A JP 2011535119A JP 5745419 B2 JP5745419 B2 JP 5745419B2
Authority
JP
Japan
Prior art keywords
cells
cell
ido
antigen
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011535119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507997A5 (enExample
JP2012507997A (ja
Inventor
ブエスチェル ドイルク
ブエスチェル ドイルク
デルア ロサ オルガ
デルア ロサ オルガ
ルオムバルド エルエウテリオ
ルオムバルド エルエウテリオ
Original Assignee
セルルエリク エス．エー．
セルルエリク エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルルエリク エス．エー．, セルルエリク エス．エー． filed Critical セルルエリク エス．エー．
Publication of JP2012507997A publication Critical patent/JP2012507997A/ja
Publication of JP2012507997A5 publication Critical patent/JP2012507997A5/ja
Application granted granted Critical
Publication of JP5745419B2 publication Critical patent/JP5745419B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011535119A 2008-11-07 2009-11-06 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法 Active JP5745419B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0820397.8 2008-11-07
GBGB0820397.8A GB0820397D0 (en) 2008-11-07 2008-11-07 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
PCT/EP2009/064788 WO2010052313A1 (en) 2008-11-07 2009-11-06 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases

Publications (3)

Publication Number Publication Date
JP2012507997A JP2012507997A (ja) 2012-04-05
JP2012507997A5 JP2012507997A5 (enExample) 2012-12-20
JP5745419B2 true JP5745419B2 (ja) 2015-07-08

Family

ID=40139550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011535119A Active JP5745419B2 (ja) 2008-11-07 2009-11-06 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法

Country Status (9)

Country Link
US (1) US9012220B2 (enExample)
EP (1) EP2361261B1 (enExample)
JP (1) JP5745419B2 (enExample)
KR (1) KR101666692B1 (enExample)
AU (1) AU2009312700B2 (enExample)
CA (1) CA2742698C (enExample)
ES (1) ES2479540T3 (enExample)
GB (1) GB0820397D0 (enExample)
WO (1) WO2010052313A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918615D0 (en) * 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
KR20140016933A (ko) * 2011-03-11 2014-02-10 타이제닉스, 에스.에이.유. 면역조절 활성을 갖는 세포군, 분리방법 및 용도들
EP3985105A1 (en) * 2020-10-16 2022-04-20 Uniwersytet Gdanski Conditioned regulatory t cell population tregs with enhanced therapeutic potential, method for obtaining of conditioned tregs and the medical use of the tregs population
EP3985106A1 (en) * 2020-10-16 2022-04-20 Uniwersytet Gdanski Conditioned regulatory t cell population with enhanced therapeutic potential, method for obtaining of regulatory t cell population and the medical use of regulatory t cell population

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395876B1 (en) * 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
EP1252897A4 (en) 2000-01-21 2003-07-30 Hisamitsu Pharmaceutical Co MEDICINES FOR GENE THERAPY
EP1501918A4 (en) * 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
EP1369114A1 (en) 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
PT1739166E (pt) * 2005-07-01 2011-09-22 Inst Nat Sante Rech Med Obtenção de células tr1 específicas para um auto-antigénio ou antigénio de alimentos a partir de uma população de pbmc ou de leucócito
SG10202001007TA (en) 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
WO2007081878A2 (en) * 2006-01-07 2007-07-19 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
CA2634072A1 (en) * 2005-12-21 2007-06-28 Universite De Montreal Markers for memory t cells and uses thereof
US20080155704A1 (en) * 2006-12-22 2008-06-26 King's College London Methods and Compositions for Determining in vivo Activity of BiP
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
US8685728B2 (en) * 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
WO2009155477A1 (en) * 2008-06-19 2009-12-23 The Trustees Of The University Of Pennsylvania Inducible regulatory t-cell generation for hematopoietic transplants

Also Published As

Publication number Publication date
US20120064031A1 (en) 2012-03-15
US9012220B2 (en) 2015-04-21
AU2009312700A1 (en) 2010-05-14
EP2361261A1 (en) 2011-08-31
KR101666692B1 (ko) 2016-10-17
EP2361261B1 (en) 2016-01-27
ES2479540T3 (es) 2016-05-20
CA2742698A1 (en) 2010-05-14
CA2742698C (en) 2017-04-18
AU2009312700B2 (en) 2014-06-26
KR20110123721A (ko) 2011-11-15
WO2010052313A1 (en) 2010-05-14
GB0820397D0 (en) 2008-12-17
JP2012507997A (ja) 2012-04-05
ES2479540T1 (es) 2014-08-20

Similar Documents

Publication Publication Date Title
CA2954534C (en) Manufacture and cryopreservation of fucosylated cells for therapeutic use
JP2017513498A (ja) 養子細胞治療製品を製造するための誘導多能性幹細胞の適用
JP6592551B2 (ja) 免疫調節活性を有する細胞集団、その調製方法、及び、その使用
IL228670A (en) Their cell populations are immunoregulatory activity, a method of isolation and uses
JP5431146B2 (ja) 免疫学的寛容および調節性前駆細胞
US20140154227A1 (en) Cell populations having immunoregulatory activity, method for isolation and uses
JP2013507945A (ja) 免疫調節活性を有する細胞集団、その製造方法及び使用
US9012220B2 (en) Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
CA3142267A1 (en) Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
US20260125646A1 (en) Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
US20250375520A1 (en) Production of immune cells
CN101083910B (zh) 用于预防和治疗移植中的免疫应答的肝脏基质细胞
WO2025125443A1 (en) Production of immune cells
Imamura A suitable conditioning regimen in allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia
HK40061122A (en) Transplant tolerance induction with carbodiimide treated tolerizing vaccine
Imamura A suitable conditioning regimen in allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140620

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150501

R150 Certificate of patent or registration of utility model

Ref document number: 5745419

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250